Memantine in moderate to severe Alzheimer's disease: an observational post-marketing study

被引：11

作者：

Rainer, Michael ^{[1
,2
]}

Wuschitz, A.

Jagsch, C. ^{[3
]}

Erb, C. ^{[4
]}

Chirikdjian, J. -J. ^{[5
]}

Mucke, H. A. M. ^{[6
]}

机构：

[1] Donauspital Sozialmed Zentrum Ost, Memory Clin, A-1220 Vienna, Austria

[2] Donauspital Sozialmed Zentrum Ost, Dept Psychiat, A-1220 Vienna, Austria

[3] Psychiat Hosp Wels, A-4600 Wels, Austria

[4] Merz Pharmaceut, D-60318 Frankfurt, Germany

[5] Zak Pharma GmbH, A-1130 Vienna, Austria

[6] HM Pharma Consultancy, A-1160 Vienna, Austria

来源：

JOURNAL OF NEURAL TRANSMISSION | 2011年 / 118卷 / 08期

关键词：

Alzheimer's disease; Dementia; Memantine; Activities of daily living; Post-marketing; 'Real-life' setting; CONTROLLED-TRIAL; DOUBLE-BLIND; DEMENTIA; DIAGNOSIS; SYMPTOMS;

D O I：

10.1007/s00702-011-0623-8

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Memantine is an N-methyl-d-aspartate (NMDA) receptor antagonist, approved for the treatment of moderate to severe Alzheimer's disease (AD). We conducted a 4-month observational, post-marketing, Austrian study of memantine in 377 outpatients with moderate to severe AD. In this 'real-life' setting, memantine was well-tolerated, and produced benefits in cognition (Mini-Mental State Examination), activities of daily living (Activities of Daily Living score), and global function (Clinical Global Impression scale). Treatment effects were apparent in both pre-treated and treatment-na < ve patient subgroups.

引用

页码：1255 / 1259

页数：5

共 25 条

[1] Long-term course and effectiveness of combination therapy in Alzheimer disease [J].